Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01775059 |
Recruitment Status
: Unknown
Verified January 2013 by Medtronic Diabetes R&D Denmark.
Recruitment status was: Not yet recruiting
First Posted
: January 24, 2013
Last Update Posted
: February 5, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a multi-center, non-randomized, and interventional study in which subjects will use the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm® VEO™ insulin pump (Sensor augmented pump) for 15 days.
The purpose of this study is to collect performance data on the Integrated sensor and infusion set for approximately 15 days, with the intention for each subject to wear 5 sets for 3 days each.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus Type I Diabetes Mellitus Type II | Device: Integrated sensor and infusion set. | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | March 2013 |
Estimated Primary Completion Date : | July 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Integrated sensor and infusion set. | Device: Integrated sensor and infusion set. |
- Accuracy endpoint [ Time Frame: 5 months ]Agreement Rate (% within 20%) using VEO Pump
- Safety endpoint [ Time Frame: 5 months ]Descriptive summary of SAE, Adverse events and Device complaints
- Accuracy endpoint [ Time Frame: 5 months ]Agreement Rate (% within 20%) using re-analyzed Guardian® REAL-Time and Paradigm® REAL-Time algorithm data
- Accuracy endpoint [ Time Frame: 5 months ]MARD(%), BIAS(mg/dl), MAD(mg/dl) during study

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is 18 years of age or older at time of screening
- Subject has a clinical diagnosis of insulin requiring diabetes, as determined by investigator.
- Subject is currently using a Medtronic Paradigm Sensor Augmented insulin pump and has been so for a minimum of 3 months at time of enrollment.
- Subject has Continuous Glucose Monitoring experience (min 30% of CGM use within the month prior to enrollment).
- Subject has an average of 3 SMBG per day (verified via CareLink) during the month prior to enrollment.
- Subject is willing to wear the study devices for the duration of the study
- Subject is willing to perform frequent (min 7 per day) SMBGs during study device wear
- Subject is willing to keep a short diary during the device wear.
Exclusion Criteria:
- Female subject is pregnant, per urine pregnancy test performed at time of enrollment in women of child bearing age.
- Female subject plans to become pregnant during the course of the study.
- Subject is unable to tolerate tape adhesive in the area of the placement of the study device.
- Subject has any unresolved adverse skin condition in the area of the placement of the study device (e.g. psoriasis, rash, Staphylococcus infection).
- The subject is not deemed to be an appropriate candidate for the study by the investigator for any reason.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01775059
Contact: Ulrik Pedersen-Bjergaard, MD | ulrik.pedersen-bjergaard@regionh.dk |
Denmark | |
Fredericia Hospital | Recruiting |
Fredericia, Denmark, 7000 | |
Contact: Hans Gjessing, MD hans.gjessing@slb.regionsyddanmark.dk | |
Principal Investigator: Hans Gjessing, MD | |
Hilleroed Hospital | Recruiting |
Hilleroed, Denmark, 3400 | |
Contact: Ulrik Pedersen-Bjergaard, MD ulrik.pedersen-bjergaard@regionh.dk | |
Principal Investigator: Ulrik Pedersen-Bjergaard, MD | |
Hvidovre Hospital | Recruiting |
Hvidovre, Denmark, 2650 | |
Contact: Kirsten Norgaard, MD kirsten.noergaard@regionh.dk | |
Principal Investigator: Kirsten Noergaard, MD |
Principal Investigator: | Ulrik Pedersen-Bjergaard, MD | Hilleroed Hospital |
Responsible Party: | Medtronic Diabetes R&D Denmark |
ClinicalTrials.gov Identifier: | NCT01775059 History of Changes |
Other Study ID Numbers: |
CEP 277 2012102304 |
First Posted: | January 24, 2013 Key Record Dates |
Last Update Posted: | February 5, 2013 |
Last Verified: | January 2013 |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |